SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485
Debt
Debt-to-Equity Ratio0.35
Current Ratio4.30
Quick Ratio4.30
Price-To-Earnings
Trailing P/E Ratio-1.36
Forward P/E Ratio-2.14
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales247.71
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book1.85
Profitability
EPS (Most Recent Fiscal Year)($1.01)
Net Income$-25,060,000.00
Net Margins-12,011.72%
Return on Equity-105.78%
Return on Assets-54.13%
Miscellaneous
Employees19
Outstanding Shares47,010,000
Market Cap$65.35 million
SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS Inc (NASDAQ:SCYX) announced its quarterly earnings data on Thursday, August, 9th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.06. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.08 million. SCYNEXIS had a negative net margin of 12,011.72% and a negative return on equity of 105.78%. View SCYNEXIS's Earnings History.
When is SCYNEXIS's next earnings date?
What price target have analysts set for SCYX?
8 analysts have issued 1-year price objectives for SCYNEXIS's shares. Their predictions range from $4.00 to $9.00. On average, they expect SCYNEXIS's stock price to reach $5.6250 in the next year. This suggests a possible upside of 310.6% from the stock's current price. View Analyst Price Targets for SCYNEXIS.
What is the consensus analysts' recommendation for SCYNEXIS?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SCYNEXIS.
What are Wall Street analysts saying about SCYNEXIS stock?
Here are some recent quotes from research analysts about SCYNEXIS stock:
- 1. Canaccord Genuity analysts commented, "We’d use any weakness in SCYX shares to build long term positions ahead of a pivotal VVC read and what could be positive data from preliminary FURI and CARES reads expected later this year." (8/14/2018)
- 2. Maxim Group analysts commented, "Scynexis reported 2Q18 with operating expenses of $7.7M and ended the period with $55M in cash, runway at the current burn rate into late 2019." (8/10/2018)
- 3. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (7/15/2018)
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include Axovant Sciences (AXON), Aratana Therapeutics (PETX), Clearside Biomedical (CLSD), Tyme Technologies (TYME), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Ocular Therapeutix (OCUL), Marinus Pharmaceuticals (MRNS), ProQR Therapeutics (PRQR), DURECT (DRRX), Neptune Technologies & Bioressources (NEPT), Protagonist Therapeutics (PTGX), Teligent (TLGT), Chimerix (CMRX), Kamada (KMDA) and Aeglea Bio Therapeutics (AGLE).
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Dr. Marco Taglietti, CEO, Pres & Director (Age 58)
- Mr. Eric Francois, Chief Financial Officer (Age 43)
- Mr. David Gonzalez Angulo, Chief Medical Officer (Age 53)
- Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 40)
- Dr. Rajeshwar Motheram, VP of Pharmaceutical Devel.
Has SCYNEXIS been receiving favorable news coverage?
News stories about SCYX stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. SCYNEXIS earned a media and rumor sentiment score of 0.05 on Accern's scale. They also assigned media headlines about the company an impact score of 48.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for SCYNEXIS.
Who are SCYNEXIS's major shareholders?
SCYNEXIS's stock is owned by many different of retail and institutional investors. Top institutional shareholders include DAFNA Capital Management LLC (2.72%), BlackRock Inc. (0.39%), Renaissance Technologies LLC (0.25%) and Kabarec Financial Advisors Ltd. (0.17%). Company insiders that own SCYNEXIS stock include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti, Patrick Machado and Scott Sukenick. View Institutional Ownership Trends for SCYNEXIS.
Which major investors are selling SCYNEXIS stock?
Which major investors are buying SCYNEXIS stock?
SCYX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Kabarec Financial Advisors Ltd. and BlackRock Inc.. Company insiders that have bought SCYNEXIS stock in the last two years include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti, Patrick Machado and Scott Sukenick. View Insider Buying and Selling for SCYNEXIS.
How do I buy shares of SCYNEXIS?
Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYX stock can currently be purchased for approximately $1.37.
How big of a company is SCYNEXIS?
SCYNEXIS has a market capitalization of $65.35 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. SCYNEXIS employs 19 workers across the globe.
How can I contact SCYNEXIS?
SCYNEXIS's mailing address is 101 HUDSON STREET SUITE 3610, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]
MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
